Morgan Stanley Maintains Overweight on Novartis, Raises Price Target to $170

Morgan Stanley analyst Mark Purcell has maintained an Overweight rating on Novartis (NYSE: NVS) and increased the price target from $143 to $170. This adjustment reflects a positive outlook on the company's performance.